Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Tuspetinib by Aptose Biosciences for Chronic Myelomonocytic Leukemia (CMML): Likelihood of Approval
Tuspetinib is under clinical development by Aptose Biosciences and currently in Phase II for Chronic Myelomonocytic Leukemia (CMML). According to...
Data Insights
Tuspetinib by Aptose Biosciences for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approval
Tuspetinib is under clinical development by Aptose Biosciences and currently in Phase II for Acute Myelocytic Leukemia (AML, Acute Myeloblastic...